Azacitidine-induced interstitial and alveolar fibrosis in a patient with myelodysplastic syndrome

Pharmacotherapy

Volumn 25, Issue 5 I, 2005, Pages 765-768

  Adams, Christopher D ^a   Szumita, Paul M ^a   Baroletti, Steven A ^a   Lilly, Craig M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Alveolar fibrosis; Azacitidine; Interstitial fibrosis; Myelodysplastic syndrome

Indexed keywords

AZACITIDINE; CEFTRIAXONE; CITALOPRAM; DOCUSATE SODIUM; ERYTHROPOIETIN; ESOMEPRAZOLE; LEVOFLOXACIN; LORAZEPAM; METHYLPREDNISOLONE; METRONIDAZOLE; ONDANSETRON; OXAZEPAM; OXYCODONE; PARACETAMOL; RECOMBINANT ERYTHROPOIETIN;

AGED; ANEMIA; ARTICLE; BONE MARROW BIOPSY; BRONCHOSCOPY; CASE REPORT; CHRONIC FATIGUE SYNDROME; COMPUTER ASSISTED TOMOGRAPHY; DEHYDRATION; FAILURE TO THRIVE; FEVER; FIBROSING ALVEOLITIS; HUMAN; LUNG BIOPSY; LUNG FUNCTION; LUNG LAVAGE; LUNG TOXICITY; MALE; MYELODYSPLASTIC SYNDROME; SYNCOPE; THORAX RADIOGRAPHY; UPPER RESPIRATORY TRACT;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; HUMANS; MALE; MYELODYSPLASTIC SYNDROMES; PULMONARY FIBROSIS;

EID: 18144406486     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.25.5.765.63579     Document Type: Article

References (31)

1. ++ cells in patients with myelodysplastic syndrome (MDS) and MDS-acute myeloid leukemia. Br J Haematol 2003;121(1):63-75.
2. Parker JE, Mufti GJ. The role of apoptosis in the pathogenesis of the myelodysplastic syndromes. Int J Hematol 2001;73:416-28.
3. Negrin RS, Haeuber DH. Maintenance treatment of patients with myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor. Blood 1990;76:36-43.
4. Aplastic Anemia & MDS International Foundation, Inc. The diseases. Available from http://www.aamds.org. Accessed July 22, 2004.
5. Pomeroy C, Oken MM, Rydell RE, Filice GA. Infection in the myelodysplastic syndromes. Am J Med 1991;90:338-44.
6. Dunbar CE, Nienhuis AW. Myelodysplastic syndromes. In: Handin RI, Lux SE, Stossel TP, eds. Blood: principles & practice of hematology. Philadelphia: JB Lippincott, 1995:377-414.
7. Koeffler HP, Golde DW. Human preleukemia. Ann Intern Med 1980;93:347-53.
8. Noel P, Solberg LA Jr. Myelodysplastic syndromes. Pathogenesis, diagnosis and treatment. Crit Rev Oncol Hematol 1992;12:193-215.
9. Greenberg P, Cox C, Le Beau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-88.
10. National Comprehensive Cancer Network. NCCN practice guidelines for the myelodysplastic syndromes. Oncology 1998;12:53-80.
11. Veit CT, Ware JE Jr. The structure of psychological distress and well-being in general populations. J Consult Clin Psychol 1983;51:730-42.
12. Holland JC, Herndon J, Kornblith AB, et al. A sociodemographic data collection model for cooperative clinical trials [abstr]. Proc Am Soc Clin Oncol 1992;11:157.
13. Leone G, Voso MT, Teofili L, Lubbert M. Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS. Clin Immunol 2003;109(1):89-102.
14. Kornblith AB, Herndon JE, Silverman LR, et al. Impact of azacitidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a cancer and leukemia group B study. J Clin Oncol 2002;20(10):2441-52.
15. Gryn J, Zeigler ZR, Shadduck RK, et al. Treatment of myelodysplastic syndromes with azacitidine. Leuk Res 2002;26(10):893-7.
16. Silverman LR, Demakos EP, Peterson BL, et al. Randomized control trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin One 2002;20(10):2429-40.
17. Pharmion. Vidaza (azacitidine) package insert. Boulder, CO; 2004.
18. Hubbard R, Venn A, Smith C, et al. Exposure to commonly prescribed drugs and the etiology of cryptogenic fibrosing alveolitis: a case-control study. Am J Respir Crit Care Med 1998;157:743-7.
19. Baumgartner KB, Samet J, Stidley CA, et al. Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1997;155:242-8.
20. Tobin RW, Pope CE II, Pellefrini CA, et al. Increased prevalence of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998;158:1804-8.
21. Baumgartner KB, Samet JM, Coultas DB, et al. Occupational and environmental risk factors for idiopathic pulmonary fibrosis: a multicenter case-control study. Collaborating centers. Am J Epidemiol 2000;152:307-15.
22. Jakab GJ. Sequential virus infections, bacterial superinfections, and fibrogenesis. Am Rev Respir Dis 1990;142:374-9.
23. Egan JJ, Woodcock AA, Stewart JP. Viruses and idiopathic pulmonary fibrosis. Eur Respir J 1997;10:1433-7.
24. Murphy A, O'Sullivan BJ. Familial fibrosing alveolitis. Ir J Med Sci 1981;150:204-9.
25. Mannino DM, Etzel RA, Parrish RG. Pulmonary fibrosis deaths in the United States, 1979-1991: an analysis of multiple-cause mortality data. Am J Respir Crit Care Med 1996;153:1548-52.
26. Panos RJ, Mortenson R, Niccoli SA, et al. Clinical deterioration in patients with idiopathic pulmonary fibrosis: causes and assessment. Am J Med 1990;88:396-404.
27. King TE, Costabel U, Cordier JF, et al. Idiopathic pulmonary fibrosis: diagnosis and treatment. Am J Respir Crit Care Med 2000;161:646-64.
28. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
29. Pavlakis N, Bell DR, Millward MJ, et al. Fatal pulmonary toxicity resulting from treatment with gemcitabine. Cancer 1997;80(2):286-91.
30. Sabria-Trias J, Bonnaud F, Sionoiac M. Severe interstitial pneumonitis related to gemcitabine. Rev Mal Respir 2002;19:645-7.
31. Pacheco Y, Pujol B, Revol A, et al. Respiratory function and alveolar biological changes under the effect of CDP-choline in pulmonary interstitial pathology: pulmonary fibrosis and sarcoidosis. Revue de Pneumologic Clinique 1985;41(2):91-100.